In this randomised multicentre prospective dose-selection phase IIb superiority trial , @ patients were randomised between doxorubicin ( n = @ ) , trabectedin ( @-hour infusion , T@h ) ( n = @ ) and trabectedin ( @-hour infusion , T@h ) ( n = @ ) .